Ribosomal protein L18a pseudogene 4 (RPL18AP4)

Ribosomal protein L18a pseudogene 4 (RPL18AP4) is a processed pseudogene of the functional ribosomal protein L18a gene (RPL18A). It is non-coding and not translated into a functional ribosomal protein. Like many ribosomal protein pseudogenes, RPL18AP4 is thought to arise from retrotransposition events. While most pseudogenes are considered non-functional, emerging research suggests some pseudogenes may have regulatory roles at the RNA level, such as acting as competing endogenous RNAs (ceRNAs) or miRNA sponges, but no such function has been specifically ascribed to RPL18AP4 itself[7][9]. There is no evidence that RPL18AP4 is a drug target, nor is it involved in major disease pathways or targeted by therapeutics. Its assignment as a pseudogene (not a protein-coding gene) means it does not belong to classical molecular families like enzyme, receptor, or ion channel, and does not fall under common disease mechanisms or therapy classes[9]. Key context: - The parent gene, RPL18A, encodes a ribosomal protein involved in the protein synthesis machinery and is associated with rare reports of disease involvement, but this does not apply to the pseudogene[1][5]. - Pseudogenes in general may be involved in RNA-mediated regulation, but this is uncharacterized for RPL18AP4[6]. - No interacting drugs or therapeutic applications are known for RPL18AP4; safety, efficacy, and biomarker roles are not established. Notes on interpretation: - This entity is not a therapeutic target, is not protein-coding, and is often excluded from drug target or disease-focused databases[9]. - The entry is not incorrect in the sense of name or spelling, but it is not a therapeutic target and should be flagged as such. - If structured data is required for target-based workflows or therapeutic databases, this entity should typically be excluded or annotated as a non-target pseudogene. Summary: RPL18AP4 (ribosomal protein L18a pseudogene 4) is a non-coding pseudogene with no current evidence of therapeutic, biomarker, or direct biological role. It does not fulfill criteria for being a drug target, and should be categorized as a pseudogene with potential, but unproven, regulatory function[7][9].

Other names

RPL18A_2_30RPL18AP4